Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO
BACKGROUND: Oncologic treatment in elderly patients is challenging, due to comorbidities, often impaired organ function, limited clinical trial evidence, inadequate guidelines and no consistent 'elderly' definition. We report exploratory sub-analyses of safety and efficacy in elderly patie...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
15 July 2011
|
| In: |
European journal of cancer
Year: 2011, Jahrgang: 47, Heft: 16, Pages: 2387-2395 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2011.06.018 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ejca.2011.06.018
|
| Verfasserangaben: | Xavier Pivot, Andreas Schneeweiss, Shailendra Verma, Christoph Thomssen, José Luis Passos-Coelho, Giovanni Benedetti, Eva Ciruelos, Roger von Moos, Hong-Tai Chang, Anja-Alexandra Duenne, David W. Miles |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1827191147 | ||
| 003 | DE-627 | ||
| 005 | 20230710095632.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221215s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2011.06.018 |2 doi | |
| 035 | |a (DE-627)1827191147 | ||
| 035 | |a (DE-599)KXP1827191147 | ||
| 035 | |a (OCoLC)1389739036 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Pivot, Xavier |e VerfasserIn |0 (DE-588)1155130502 |0 (DE-627)1016504047 |0 (DE-576)501443800 |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer |b results from AVADO |c Xavier Pivot, Andreas Schneeweiss, Shailendra Verma, Christoph Thomssen, José Luis Passos-Coelho, Giovanni Benedetti, Eva Ciruelos, Roger von Moos, Hong-Tai Chang, Anja-Alexandra Duenne, David W. Miles |
| 264 | 1 | |c 15 July 2011 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 15.12.2022 | ||
| 520 | |a BACKGROUND: Oncologic treatment in elderly patients is challenging, due to comorbidities, often impaired organ function, limited clinical trial evidence, inadequate guidelines and no consistent 'elderly' definition. We report exploratory sub-analyses of safety and efficacy in elderly patients, defined as ⩾ 65years old, in AVastin And DOcetaxel (AVADO) receiving first-line bevacizumab plus docetaxel for metastatic breast cancer (mBC). - PATIENTS AND METHODS: Patients with HER2-negative, locally recurrent or mBC were randomised to 3-weekly docetaxel (100mg/m(2)) with placebo, bevacizumab 7.5mg/kg or bevacizumab 15 mg/kg, for 9 cycles or until disease progression or unacceptable toxicity. Patients had no prior chemotherapy for mBC. - RESULTS: Progression-free survival (PFS) was increased with bevacizumab in the elderly subpopulation (n=127), the effect being greater with higher dose (hazard ratio=0.63 [95% confidence interval (CI) 0.383-1.032] versus 0.76 [95% CI: 0.46-1.262], respectively). PFS was numerically similar in the elderly and overall populations, but the former failed to achieve statistical significance. Overall response rates for docetaxel plus placebo, bevacizumab 7.5mg/kg and 15 mg/kg were 44.7%, 36.6% and 50.0%, respectively. Effects on survival were not statistically significant. Bevacizumab was well tolerated in elderly patients, the most common adverse effects were neutropenia and febrile neutropenia; there was no excess of grade⩾3 cardiovascular events. There was no clear correlation between baseline hypertension and its development during study treatment. - CONCLUSIONS: In this exploratory sub-analysis in AVADO, bevacizumab plus docetaxel showed efficacy in elderly patients similar to the overall study population. There were no unexpected safety signals in patients aged 65 years or older. | ||
| 650 | 4 | |a Adult | |
| 650 | 4 | |a Aged | |
| 650 | 4 | |a Aged, 80 and over | |
| 650 | 4 | |a Angiogenesis Inhibitors | |
| 650 | 4 | |a Antibodies, Monoclonal, Humanized | |
| 650 | 4 | |a Antineoplastic Agents | |
| 650 | 4 | |a Bevacizumab | |
| 650 | 4 | |a Breast Neoplasms | |
| 650 | 4 | |a Disease-Free Survival | |
| 650 | 4 | |a Docetaxel | |
| 650 | 4 | |a Drug Therapy, Combination | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Middle Aged | |
| 650 | 4 | |a Neoplasm Metastasis | |
| 650 | 4 | |a Neoplasm Recurrence, Local | |
| 650 | 4 | |a Taxoids | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a Verma, Shailendra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thomssen, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Passos-Coelho, José Luis |e VerfasserIn |4 aut | |
| 700 | 1 | |a Benedetti, Giovanni |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ciruelos, Eva |e VerfasserIn |4 aut | |
| 700 | 1 | |a von Moos, Roger |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chang, Hong-Tai |e VerfasserIn |4 aut | |
| 700 | 1 | |a Duenne, Anja-Alexandra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Miles, David W. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 47(2011), 16, Seite 2387-2395 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer results from AVADO |
| 773 | 1 | 8 | |g volume:47 |g year:2011 |g number:16 |g pages:2387-2395 |g extent:9 |a Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer results from AVADO |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2011.06.018 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20221215 | ||
| 993 | |a Article | ||
| 994 | |a 2011 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |d 50000 |e 910000PS109972554 |e 910400PS109972554 |e 50000PS109972554 |k 0/910000/ |k 1/910000/910400/ |k 0/50000/ |p 2 | ||
| 999 | |a KXP-PPN1827191147 |e 4231702713 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"9 S."}],"id":{"eki":["1827191147"],"doi":["10.1016/j.ejca.2011.06.018"]},"title":[{"title":"Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer","subtitle":"results from AVADO","title_sort":"Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2011","dateIssuedDisp":"15 July 2011"}],"relHost":[{"language":["eng"],"part":{"issue":"16","pages":"2387-2395","extent":"9","text":"47(2011), 16, Seite 2387-2395","year":"2011","volume":"47"},"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"pubHistory":["28.1992 -"],"disp":"Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer results from AVADOEuropean journal of cancer","type":{"media":"Online-Ressource","bibl":"periodical"},"corporate":[{"display":"European Organization for Research on Treatment of Cancer","role":"isb"},{"role":"isb","display":"European Association for Cancer Research"},{"display":"European School of Oncology","role":"isb"}],"titleAlt":[{"title":"EJC online"}],"recId":"266883400","title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"id":{"eki":["266883400"],"issn":["1879-0852"],"zdb":["1468190-0"]},"origin":[{"publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","dateIssuedKey":"1992","dateIssuedDisp":"1992-","publisher":"Elsevier ; Pergamon Press"}]}],"name":{"displayForm":["Xavier Pivot, Andreas Schneeweiss, Shailendra Verma, Christoph Thomssen, José Luis Passos-Coelho, Giovanni Benedetti, Eva Ciruelos, Roger von Moos, Hong-Tai Chang, Anja-Alexandra Duenne, David W. Miles"]},"language":["eng"],"note":["Gesehen am 15.12.2022"],"recId":"1827191147","person":[{"family":"Pivot","role":"aut","given":"Xavier","display":"Pivot, Xavier"},{"given":"Andreas","display":"Schneeweiss, Andreas","role":"aut","family":"Schneeweiss"},{"role":"aut","family":"Verma","display":"Verma, Shailendra","given":"Shailendra"},{"role":"aut","family":"Thomssen","display":"Thomssen, Christoph","given":"Christoph"},{"display":"Passos-Coelho, José Luis","given":"José Luis","role":"aut","family":"Passos-Coelho"},{"display":"Benedetti, Giovanni","given":"Giovanni","family":"Benedetti","role":"aut"},{"family":"Ciruelos","role":"aut","given":"Eva","display":"Ciruelos, Eva"},{"role":"aut","family":"von Moos","given":"Roger","display":"von Moos, Roger"},{"role":"aut","family":"Chang","display":"Chang, Hong-Tai","given":"Hong-Tai"},{"role":"aut","family":"Duenne","given":"Anja-Alexandra","display":"Duenne, Anja-Alexandra"},{"role":"aut","family":"Miles","given":"David W.","display":"Miles, David W."}]} | ||
| SRT | |a PIVOTXAVIEEFFICACYAN1520 | ||